Healthcare Professionals

We recognize the impact of chronic conditions on patients, caregivers, and you—clinicians navigating the mental health landscape.

Overcoming the status quo

Information found on this page is intended for US residents only.

We prioritize trust through action. We’re the first to ground classic psychedelics in the rigorous development pathways of mainstream medicine with the goal of offering providers like you new options for your hardest-to-treat patients.
 

While clinicians have worked tirelessly to support their patients, current care options for mental health conditions leave millions of patients to cycle through treatments as they search for relief. We recognize this clinical challenge and honor the perseverance of clinicians who keep seeking new answers even as patients stop expecting them. 

Like you, we understand that every mental health journey is unique and different. We don’t promise a cure, but rather the prospect of a new approach—one grounded in bringing non-traditional treatments into a rigorous medical and scientific framework. By setting high clinical standards and navigating the regulatory route for psilocybin treatment, we aim to create pathways to activate neuroplasticity, the brain’s inherent capacity for cognitive flexibility and reorganization. 

We’re driven to advance potentially clinically meaningful, rapid and durable treatment options based on a robust and meticulously-built evidence base—options designed to empower clinicians, support patient agency, and integrate into mainstream care. 

Treatment-resistant depression (TRD)

When a patient is diagnosed with TRD, it means their depression has resisted at least two courses of treatment. This resistance increases risks to their health and harm to their quality of life.¹ We are dedicated to these patients who have exhausted the current options and need science to rigorously pursue new possibilities. 

Post-traumatic stress disorder (PTSD)

PTSD is a condition that may occur in people who have experienced traumatic events,² from combat or assault to accidents or natural disasters. This state of hypervigilance often complicates life with intense comorbid distress. We are committed to your patients whose lives have been devastated by PTSD and seek a path through it. 

Quantifying the clinical necessity for change.

This status quo is unacceptable to us, and that drives our work forward—for the sake of providers like you and the patients you treat.

  • $282B

    is the annual economic cost of mental illness in the US.3

  • ~50%

    of the 61.5M US adults with a mental illness did not receive treatment in 2024.4

  • 1 in 2

    is the estimated number of US adult patients with a mental illness who don't adhere to their prescribed course of treatment.5

  • 93%

    of behavioral health workers say they've experienced burnout.6

Compass Redefine PTSD study

We encourage you to visit redefineptsdstudy.com to learn more about this clinical trial.

View Redefine

Compass has awarded grants to five qualified organizations to develop independent US-based HCP training programs for future delivery of COMP360, if FDA approved.

CME Outfitters

Jointly accredited medical education expertise

Emory University

University-based medical education and clinical training

Fluence

Established psychedelic education and training

Integrative Psychiatry Institute

Comprehensive psychedelic education and training

Strata Mental Health Solutions

Clinical trial informed support provider training and implementation guidance

Compass training documents

Separate guidance documents for US-based organizations interested in developing trainings are available upon request at [email protected]

Mail to USMedInfo

Continue exploring